Scientists found that HMG-CoA reductase (HMGCR), a crucial enzyme in the mevalonate pathway for sterol biosynthesis, is elevated in enzalutamide-resistant prostate cancer cell lines. HMGCR knockdown could re-sensitize these cells to the drug, and HMGCR overexpression conferred resistance to it, suggesting that aberrant HMGCR expression is an important enzalutamide resistance mechanism in prostate cancer cells. [J Biol Chem]
Abstract | Full Article

Investigators found that Ykt6 acts as a negative regulator of migration and invasion of human prostate epithelial cells. Furthermore, Ykt6 regulated the integrity of epithelial adherens and tight junctions. The observed anti-migratory activity of Ykt6 was mediated by a unique mechanism involving the expressional upregulation of microRNA 145, which selectively decreased the cellular level of junctional adhesion molecule A. [Cell Cycle]
Abstract

The authors developed a powerful microarray platform for a sensitive, specific and high-throughput analysis of protein O-GlcNAcylation. The developed array biochip was then utilized to parallelly analyze the O-GlcNAcylation of three oncogenic transcription factors C-Myc, NF-κB and p53 in normal prostate epithelial cell and prostate cancer cell line. [Anal Biochem]
Abstract

The authors outline the most recent pre- and clinical- data on the current status of niclosamide in the treatment of ARV7-positive castrate resistant prostate cancer patients. [Invest New Drugs]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the prostate cell research field.

The Australian Government will provide medical research funding for prostate cancer and infertility, marking the first step towards a new National Male Health Strategy. [Commonwealth of Australia]
Press Release

Harpoon Therapeutics announced that the first patient has been treated with HPN424 in a Phase I clinical study of mCRPC patients. HPN424 is the first of multiple compounds in development that are based on the company’s Tri-specific T cell Activating Construct platform and designed to penetrate solid tumors, have extended serum half-life, and recruit patients’ own T cells to destroy malignant tumor cells. [Harpoon Therapeutics]
Press Release

Lawmakers in the US Congress are running out of time to pass a budget for the 2019 fiscal year, and have yet to resolve major disagreements over climate-change and environment programs. [Nature News]
Editorial